Review: Dendritic cell immunotherapy for melanoma

May Hadzantonis, Helen O'Neill

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Melanoma is a particularly aggressive malignant tumour of the skin that is influenced by genetic, environmental and physiological elements. Since current therapy for melanoma is limited and associated with high toxicity and side effects, development of alternative approaches is imperative. The importance of dendritic cells (DCs) in immunity against tumours is now well established DC immunotherapy for melanoma is possible but must be considered in terms of effectiveness and clinical viability. The source of DCs to be used in adoptive therapy as well as the nature and method of delivery of the priming antigen are important factors. The most suitable DC appears to be cells derived by culture from hemopoietic progenitor cells (HPC) in bone marrow or DC progenitors in peripheral blood generation of an effective anti- tumour immune response will be dependent upon the presentation of multiple melanoma-specific antigens by both major histocompatibility complex (MHC) class I and class II molecules and stimulation of both tumour-specific cytotoxic T lymphocytes (Tc) and T helper type 1 (Th1) cells. Different techniques for delivery of the priming antigen offer different advantages. DCs can be pulsed with peptide, protein or tumour cell lysate, transfected with viral vectors or naked nucleic acid and tumour/DC hybridomas can also be generated. Repeated antigen administration into neighbouring lymph nodes appears to be the most effective method for promoting a systemic anti-tumour response. Adjuvant therapies can also enhance immune responses and lead to total tumour clearance. The importance of DC immunotherapy in clinically different stages of disease will also be an important consideration.

Original languageEnglish
Pages (from-to)11-22
Number of pages12
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number1
DOIs
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Immunotherapy
Dendritic Cells
Melanoma
Neoplasms
Antigens
Melanoma-Specific Antigens
Th1 Cells
Hybridomas
Cytotoxic T-Lymphocytes
Major Histocompatibility Complex
Bone Marrow Cells
Nucleic Acids
Immunity
Stem Cells
Therapeutics
Cell Culture Techniques
Lymph Nodes
Skin
Peptides
Proteins

Cite this

@article{9d74360ba9a3435eafb5a0ab331049b4,
title = "Review: Dendritic cell immunotherapy for melanoma",
abstract = "Melanoma is a particularly aggressive malignant tumour of the skin that is influenced by genetic, environmental and physiological elements. Since current therapy for melanoma is limited and associated with high toxicity and side effects, development of alternative approaches is imperative. The importance of dendritic cells (DCs) in immunity against tumours is now well established DC immunotherapy for melanoma is possible but must be considered in terms of effectiveness and clinical viability. The source of DCs to be used in adoptive therapy as well as the nature and method of delivery of the priming antigen are important factors. The most suitable DC appears to be cells derived by culture from hemopoietic progenitor cells (HPC) in bone marrow or DC progenitors in peripheral blood generation of an effective anti- tumour immune response will be dependent upon the presentation of multiple melanoma-specific antigens by both major histocompatibility complex (MHC) class I and class II molecules and stimulation of both tumour-specific cytotoxic T lymphocytes (Tc) and T helper type 1 (Th1) cells. Different techniques for delivery of the priming antigen offer different advantages. DCs can be pulsed with peptide, protein or tumour cell lysate, transfected with viral vectors or naked nucleic acid and tumour/DC hybridomas can also be generated. Repeated antigen administration into neighbouring lymph nodes appears to be the most effective method for promoting a systemic anti-tumour response. Adjuvant therapies can also enhance immune responses and lead to total tumour clearance. The importance of DC immunotherapy in clinically different stages of disease will also be an important consideration.",
author = "May Hadzantonis and Helen O'Neill",
year = "1999",
doi = "10.1089/cbr.1999.14.11",
language = "English",
volume = "14",
pages = "11--22",
journal = "Antibody, Immunoconjugates, and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "MARY ANN LIEBERT INC PUBL",
number = "1",

}

Review : Dendritic cell immunotherapy for melanoma. / Hadzantonis, May; O'Neill, Helen.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 14, No. 1, 1999, p. 11-22.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Review

T2 - Dendritic cell immunotherapy for melanoma

AU - Hadzantonis, May

AU - O'Neill, Helen

PY - 1999

Y1 - 1999

N2 - Melanoma is a particularly aggressive malignant tumour of the skin that is influenced by genetic, environmental and physiological elements. Since current therapy for melanoma is limited and associated with high toxicity and side effects, development of alternative approaches is imperative. The importance of dendritic cells (DCs) in immunity against tumours is now well established DC immunotherapy for melanoma is possible but must be considered in terms of effectiveness and clinical viability. The source of DCs to be used in adoptive therapy as well as the nature and method of delivery of the priming antigen are important factors. The most suitable DC appears to be cells derived by culture from hemopoietic progenitor cells (HPC) in bone marrow or DC progenitors in peripheral blood generation of an effective anti- tumour immune response will be dependent upon the presentation of multiple melanoma-specific antigens by both major histocompatibility complex (MHC) class I and class II molecules and stimulation of both tumour-specific cytotoxic T lymphocytes (Tc) and T helper type 1 (Th1) cells. Different techniques for delivery of the priming antigen offer different advantages. DCs can be pulsed with peptide, protein or tumour cell lysate, transfected with viral vectors or naked nucleic acid and tumour/DC hybridomas can also be generated. Repeated antigen administration into neighbouring lymph nodes appears to be the most effective method for promoting a systemic anti-tumour response. Adjuvant therapies can also enhance immune responses and lead to total tumour clearance. The importance of DC immunotherapy in clinically different stages of disease will also be an important consideration.

AB - Melanoma is a particularly aggressive malignant tumour of the skin that is influenced by genetic, environmental and physiological elements. Since current therapy for melanoma is limited and associated with high toxicity and side effects, development of alternative approaches is imperative. The importance of dendritic cells (DCs) in immunity against tumours is now well established DC immunotherapy for melanoma is possible but must be considered in terms of effectiveness and clinical viability. The source of DCs to be used in adoptive therapy as well as the nature and method of delivery of the priming antigen are important factors. The most suitable DC appears to be cells derived by culture from hemopoietic progenitor cells (HPC) in bone marrow or DC progenitors in peripheral blood generation of an effective anti- tumour immune response will be dependent upon the presentation of multiple melanoma-specific antigens by both major histocompatibility complex (MHC) class I and class II molecules and stimulation of both tumour-specific cytotoxic T lymphocytes (Tc) and T helper type 1 (Th1) cells. Different techniques for delivery of the priming antigen offer different advantages. DCs can be pulsed with peptide, protein or tumour cell lysate, transfected with viral vectors or naked nucleic acid and tumour/DC hybridomas can also be generated. Repeated antigen administration into neighbouring lymph nodes appears to be the most effective method for promoting a systemic anti-tumour response. Adjuvant therapies can also enhance immune responses and lead to total tumour clearance. The importance of DC immunotherapy in clinically different stages of disease will also be an important consideration.

UR - http://www.scopus.com/inward/record.url?scp=0032897554&partnerID=8YFLogxK

U2 - 10.1089/cbr.1999.14.11

DO - 10.1089/cbr.1999.14.11

M3 - Article

VL - 14

SP - 11

EP - 22

JO - Antibody, Immunoconjugates, and Radiopharmaceuticals

JF - Antibody, Immunoconjugates, and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -